Cancer Genetics Appoints Renowned Biotech Entrepreneur Dr. Thomas F. Widmann to its Board of Directors
27 nov. 2017 08h00 HE
|
Cancer Genetics, Inc.
RUTHERFORD, N.J., Nov. 27, 2017 (GLOBE NEWSWIRE) -- Cancer Genetics, Inc. (Nasdaq:CGIX), a leader in enabling precision medicine for oncology through molecular markers and diagnostics, today...
Cancer Genetics Reports Record Third Quarter 2017 Revenue and 134% Increase in Contracted Bookings from Major Biotech and Pharmaceutical Companies
09 nov. 2017 07h22 HE
|
Cancer Genetics, Inc.
Actively Working with 9 of Top 10 Biopharma Companies Globally Revenue Increased 19% to $8.0 Million, Gross Margin Improved to 43% Conference call at 8:30 a.m. EST, Thursday, November 9, 2017 ...
Cancer Genetics to Present Insights to Advance Precision Medicine in Non-Small Cell Lung Cancer (NSCLC) at AMP Annual Meeting 2017
08 nov. 2017 07h30 HE
|
Cancer Genetics, Inc.
The two presentations at AMP highlight the role of next-generation sequencing in lung cancer biomarker testing, including CGI’s liquid biopsy test, Liquid::Lung-cfDNA™Thermo Fisher’s next-generation...
Cancer Genetics, Inc. is Among the First To Drive New FDA-Approved Testing Paradigm for Non-Small Cell Lung Cancer Patients by Offering Thermo Fisher Scientific’s Oncomine Dx Target Test
02 nov. 2017 07h30 HE
|
Cancer Genetics, Inc.
Thermo Fisher’s multi-biomarker test helps match lung cancer patients to FDA-approved therapies in days instead of weeksCGI and Thermo Fisher are collaborating with pharmaceutical partners and...
Cancer Genetics Announces Timing for Third Quarter 2017 Earnings Call & Update on vivoPharm Integration on Thursday, November 9th
01 nov. 2017 10h42 HE
|
Cancer Genetics, Inc.
RUTHERFORD, N.J., Nov. 01, 2017 (GLOBE NEWSWIRE) -- Cancer Genetics, Inc. (Nasdaq:CGIX) a leader in enabling precision medicine for oncology through molecular markers and diagnostics, announced...
Cancer Genetics Named One of the Top 10 Drug Discovery & Development Solution Providers by Panel of Industry Experts at Pharma Tech Outlook
31 oct. 2017 07h45 HE
|
Cancer Genetics, Inc.
RUTHERFORD, N.J., Oct. 31, 2017 (GLOBE NEWSWIRE) -- Cancer Genetics, Inc. (Nasdaq:CGIX) (“CGI” or “The Company”), a leader in enabling precision medicine for oncology through molecular markers and...
Cancer Genetics, Inc. – a Leader in Personalized Medicine – Launches AntigenID™, Solidifying CGI’s Position as a Precision Oncology Leader in the Fast Growing, Rapidly-Evolving Field of Immuno-Oncology Therapy & Drug Development
30 oct. 2017 08h03 HE
|
Cancer Genetics, Inc.
CGI’s AntigenID™ identifies neoantigens and neoantigen signatures that accelerate immuno-oncology drug identification, predict patient-specific immune therapy response, and help create personalized...
Cancer Genetics, Inc. to Host Panel Discussion on “The Convergence of Artificial Intelligence and Healthcare - New Developments in Precision Medicine” During the 3rd Annual Dawson James Small Cap Growth Conference on October 18th
12 oct. 2017 07h30 HE
|
Cancer Genetics, Inc.
Cancer Genetics Will Also Present a Corporate Overview on Thursday, October 19th RUTHERFORD, N.J., Oct. 12, 2017 (GLOBE NEWSWIRE) -- Cancer Genetics, Inc. (Nasdaq:CGIX) (“CGI” or “The Company”), a...
Cancer Genetics, Inc. to Present at The MicroCap Conference on October 5th in New York City at the Essex House
29 sept. 2017 07h30 HE
|
Cancer Genetics, Inc.
RUTHERFORD, N.J., Sept. 29, 2017 (GLOBE NEWSWIRE) -- Cancer Genetics, Inc. (Nasdaq:CGIX) (the Company and CGI), a leader in enabling precision medicine for oncology through molecular markers and...
Cancer Genetics, Inc. to Present at the 2017 Disruptive Growth Company Showcase NYC on September 27th
22 sept. 2017 08h00 HE
|
Cancer Genetics, Inc.
RUTHERFORD, N.J., Sept. 22, 2017 (GLOBE NEWSWIRE) -- Cancer Genetics, Inc. (Nasdaq:CGIX) (the Company and CGI), a leader in enabling precision medicine for oncology through molecular markers and...